115 related articles for article (PubMed ID: 35617132)
1. Brinzolamide- and latanoprost-loaded nano lipid carrier prevents synergistic retinal damage in glaucoma.
Chen L; Wu R
Acta Biochim Pol; 2022 May; 69(2):423-428. PubMed ID: 35617132
[TBL] [Abstract][Full Text] [Related]
2. Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery.
Shrivastava N; Khan S; Baboota S; Ali J
Curr Drug Deliv; 2018; 15(6):829-839. PubMed ID: 29189155
[TBL] [Abstract][Full Text] [Related]
3. Dual Drug Loaded Lipid Nanocarrier Formulations for Topical Ocular Applications.
Youssef AAA; Dudhipala N; Majumdar S
Int J Nanomedicine; 2022; 17():2283-2299. PubMed ID: 35611213
[TBL] [Abstract][Full Text] [Related]
4. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
5. Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study.
Dubey V; Mohan P; Dangi JS; Kesavan K
Int J Biol Macromol; 2020 Jun; 152():1224-1232. PubMed ID: 31751741
[TBL] [Abstract][Full Text] [Related]
6. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study.
Zafar A
J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278
[TBL] [Abstract][Full Text] [Related]
7. Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma.
Bessone CDV; Akhlaghi SP; Tártara LI; Quinteros DA; Loh W; Allemandi DA
Eur J Pharm Sci; 2021 May; 160():105748. PubMed ID: 33567324
[TBL] [Abstract][Full Text] [Related]
8. PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma.
Salama HA; Ghorab M; Mahmoud AA; Abdel Hady M
AAPS PharmSciTech; 2017 Oct; 18(7):2517-2528. PubMed ID: 28224390
[TBL] [Abstract][Full Text] [Related]
9. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
10. Brinzolamide loaded core-shell nanoparticles for enhanced coronial penetration in the treatment of glaucoma.
Song J; Zhang Z
J Appl Biomater Funct Mater; 2020; 18():2280800020942712. PubMed ID: 33151769
[TBL] [Abstract][Full Text] [Related]
11. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
12. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of single glaucoma drug in combined timolol XE, latanoprost and brinzolamide therapy: a discontinuation study.
Kobayashi H
J Ocul Pharmacol Ther; 2012 Jun; 28(3):245-50. PubMed ID: 22283238
[TBL] [Abstract][Full Text] [Related]
14. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma.
Nakamoto K; Yasuda N
J Glaucoma; 2007; 16(4):352-7. PubMed ID: 17570997
[TBL] [Abstract][Full Text] [Related]
15. The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost.
Li Yim JF; Montgomery DM
Curr Med Res Opin; 2011 Aug; 27(8):1499-502. PubMed ID: 21651425
[TBL] [Abstract][Full Text] [Related]
16. An Ex Vivo Evaluation of Moxifloxacin Nanostructured Lipid Carrier Enriched In Situ Gel for Transcorneal Permeation on Goat Cornea.
Gade S; Patel KK; Gupta C; Anjum MM; Deepika D; Agrawal AK; Singh S
J Pharm Sci; 2019 Sep; 108(9):2905-2916. PubMed ID: 30978345
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
18. Cubogel as potential platform for glaucoma management.
Sayed S; Abdel-Moteleb M; Amin MM; Khowessah OM
Drug Deliv; 2021 Dec; 28(1):293-305. PubMed ID: 33509004
[TBL] [Abstract][Full Text] [Related]
19. Design and dermatokinetic evaluation of Apremilast loaded nanostructured lipid carriers embedded gel for topical delivery: A potential approach for improved permeation and prolong skin deposition.
Rapalli VK; Sharma S; Roy A; Singhvi G
Colloids Surf B Biointerfaces; 2021 Oct; 206():111945. PubMed ID: 34216849
[TBL] [Abstract][Full Text] [Related]
20. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
Wang W; Chen L; Huang X; Shao A
AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
